Brain-Derived Neurotrophic Factor (BDNF)

Brain-derived neurotrophic factor (BDNF) is the most abundant and widely studied neurotrophin in the mammalian brain. First purified from pig brain by Yves-Alain Barde and Hans Thoenen in 1982, BDNF belongs to the neurotrophin family alongside nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). It is encoded by the BDNF gene on chromosome 11p14.1 in humans and is synthesized as a precursor protein (proBDNF) that is proteolytically cleaved to yield the mature, biologically active form.

BDNF plays a central role in neuronal survival, synaptic plasticity, learning, and memory. Its relevance to peptide science is direct: several neuroprotective and nootropic peptides exert their effects at least partly through modulation of BDNF expression and signaling.

Biological functions

Neuron survival and development

During brain development, BDNF provides trophic support to developing neurons, promoting their survival and differentiation. Neurons that fail to receive adequate neurotrophic signaling undergo programmed cell death (apoptosis). In the adult brain, BDNF continues to support neuronal viability, particularly in the hippocampus, cortex, and basal forebrain cholinergic neurons — regions critical for learning and memory.

Synaptic plasticity and long-term potentiation

BDNF is one of the most important molecular mediators of synaptic plasticity — the ability of synapses to strengthen or weaken in response to activity. It is required for long-term potentiation (LTP), the cellular mechanism widely regarded as the foundation of learning and memory formation. BDNF enhances neurotransmitter release from presynaptic terminals, promotes dendritic spine growth, and facilitates the insertion of AMPA receptors into postsynaptic membranes, all of which strengthen synaptic transmission.

Neurogenesis

BDNF promotes adult hippocampal neurogenesis — the birth of new neurons in the dentate gyrus of the hippocampus, one of only two brain regions where neurogenesis persists into adulthood. This process is linked to mood regulation, stress resilience, and cognitive flexibility.

Neurotransmitter modulation

BDNF regulates the synthesis, release, and receptor expression of several neurotransmitter systems, including glutamate, GABA, serotonin, and dopamine. Its influence on serotonergic signaling is particularly relevant to mood disorders.

The TrkB signaling pathway

Mature BDNF signals primarily through tropomyosin receptor kinase B (TrkB), a receptor tyrosine kinase. BDNF binding causes TrkB dimerization and autophosphorylation, activating three major downstream cascades:

• MAPK/ERK pathway — promotes neuronal differentiation, survival, and synaptic plasticity. ERK signaling activates CREB (cAMP response element-binding protein), a transcription factor that drives expression of genes essential for long-term memory consolidation.
• PI3K/Akt pathway — provides anti-apoptotic survival signaling. Akt phosphorylates and inactivates pro-apoptotic proteins (BAD, caspase-9), promoting neuronal survival under stress conditions.
• PLCgamma pathway — generates inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to intracellular calcium release and protein kinase C (PKC) activation. This pathway modulates synaptic plasticity and neurotransmitter release.

ProBDNF (the uncleaved precursor) signals through a separate receptor, p75NTR, and generally promotes apoptosis and synaptic weakening (long-term depression) — functionally opposing mature BDNF. The balance between proBDNF/p75NTR and mature BDNF/TrkB signaling is increasingly recognized as important in both normal brain function and disease.

The Val66Met polymorphism

The most clinically significant genetic variant affecting BDNF is the Val66Met polymorphism (rs6265), a single nucleotide change that substitutes valine for methionine at position 66 of the proBDNF sequence. This substitution does not alter the mature BDNF protein itself but impairs the intracellular trafficking and activity-dependent secretion of BDNF.

Approximately 20-30% of Caucasian populations and up to 50-70% of East Asian populations carry at least one Met allele. Carriers show reduced hippocampal volume on neuroimaging, impaired episodic memory performance, and altered cortical plasticity. The Val66Met variant has been associated with increased susceptibility to depression, anxiety disorders, PTSD, and poorer recovery from traumatic brain injury, though effect sizes are modest and depend on gene-environment interactions.

Factors that modulate BDNF levels

Factors that increase BDNF

• Exercise — aerobic exercise is the most potent natural BDNF inducer. A single bout of moderate-intensity exercise can transiently increase peripheral BDNF levels by 2-3 fold, and regular exercise training elevates baseline BDNF. The effect is dose-dependent and particularly robust with sustained aerobic activity.
• Sleep — adequate sleep, particularly slow-wave sleep, supports BDNF expression. Sleep deprivation reduces hippocampal BDNF in animal models and is associated with lower serum BDNF in humans.
• Sunlight and vitamin D — vitamin D receptor activation has been linked to BDNF gene expression, and seasonal studies report higher BDNF levels in summer months.
• Diet — caloric restriction, intermittent fasting, and diets rich in polyphenols (flavonoids, curcumin) and omega-3 fatty acids have been shown to upregulate BDNF expression in preclinical models.
• Social enrichment and cognitive stimulation — environmental enrichment increases hippocampal BDNF in animal models, paralleling human observations that cognitive engagement supports brain health.

Factors that decrease BDNF

• Chronic stress — sustained glucocorticoid exposure (cortisol in humans, corticosterone in rodents) suppresses BDNF transcription in the hippocampus, contributing to stress-related hippocampal atrophy.
• Aging — BDNF levels decline with age in both the brain and periphery, correlating with age-related cognitive decline.
• High-sugar and high-fat diets — Western-pattern diets reduce hippocampal BDNF in rodent studies.
• Sedentary behavior — physical inactivity is associated with lower circulating BDNF.
• Chronic inflammation — sustained systemic inflammation (elevated TNF-alpha, IL-6) suppresses BDNF expression.

BDNF in disease

Depression

The neurotrophic hypothesis of depression posits that reduced BDNF signaling in the hippocampus and prefrontal cortex contributes to the pathophysiology of major depressive disorder. Postmortem studies consistently show decreased BDNF levels in the hippocampus of depressed individuals. Most antidepressants (SSRIs, SNRIs, tricyclics) increase BDNF expression over the course of chronic treatment, and ketamine's rapid antidepressant action involves rapid BDNF release and TrkB activation. Serum BDNF levels are reduced in untreated depressed patients and normalize with successful treatment, though peripheral BDNF is an imperfect proxy for central nervous system levels.

Alzheimer's disease

BDNF levels are reduced in the hippocampus and entorhinal cortex early in Alzheimer's disease, preceding significant neuronal loss. Reduced BDNF may impair synaptic maintenance and render neurons more vulnerable to amyloid-beta toxicity. Val66Met carriers show accelerated cognitive decline in Alzheimer's.

Post-traumatic stress disorder

PTSD is associated with reduced peripheral BDNF levels and impaired fear extinction learning, a process dependent on BDNF signaling in the prefrontal cortex and amygdala.

How peptides modulate BDNF

Several peptides studied in neuroscience research influence BDNF signaling:

• Semax — a synthetic analog of ACTH(4-10), Semax has been shown to increase BDNF mRNA expression in the rat hippocampus and cortex. It also upregulates TrkB receptor expression, potentially amplifying BDNF signaling.
• Cerebrolysin — a porcine brain-derived peptide mixture, Cerebrolysin contains neurotrophic peptide fragments and has been shown to increase BDNF levels in clinical and preclinical studies, particularly in stroke and traumatic brain injury models.
• Selank — a synthetic analog of the immunomodulatory peptide tuftsin, Selank increases BDNF mRNA in the hippocampus in rodent models and has shown anxiolytic properties potentially related to this mechanism.

These peptides do not replace BDNF directly; rather, they modulate the transcription, processing, or receptor signaling associated with endogenous BDNF. The clinical significance of these findings remains an area of active investigation, with most human data coming from small trials or post-Soviet clinical literature that awaits replication in larger, controlled studies.

Measurement considerations

BDNF is commonly measured in serum or plasma, but interpreting these values requires caution. Platelets store large quantities of BDNF and release it during clotting, so serum BDNF concentrations are substantially higher (20-100 fold) than plasma levels and are influenced by platelet count and sample handling. Peripheral BDNF levels do not directly reflect brain BDNF concentrations, though animal studies show some correlation between hippocampal and serum BDNF under certain conditions. Standardized blood draw protocols, consistent use of serum versus plasma, and awareness of confounding variables (time of day, recent exercise, medications) are essential for meaningful BDNF measurement in research or clinical contexts.